低剂量重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死有效性及安全性研究

被引：21

作者：

玄丽慧

张娴娴

易琼

景坚

沈雪

徐亮

陈应柱

李军

朱艳

机构：

[1] 扬州大学临床医学院神经内科

来源：

中华老年心脑血管病杂志 | 2013年 / 15卷 / 10期

关键词：

脑梗死; 颅内出血; 组织型纤溶酶原激活物; 预后;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

摘要：

目的探讨发病时间3～4.5h内脑梗死患者应用0.6mg/kg重组组织型纤溶酶原激活剂(recombinant tissue-type plasminogen actiator,rt-PA)治疗的有效性及安全性。方法选择发病3～4.5h内脑梗死患者44例(脑梗死组),给予0.6mg/kg rt-PA静脉溶栓治疗,30、90d随访时,应用美国国立卫生研究院卒中量表(national institutes of health stroke scale,NIHSS)评分及改良Rankins评分(modified Rankin scale,mRS)评估其神经功能恢复和临床疗效,观察溶栓后的症状性颅内出血(symptomatic intracerebral hemorrage,sICH)发生率。将所有的观察结果与ECASSⅢ(European Cooperative Acute Stroke StudyⅢ)试验的相应结果进行对比(0.9mg/kg rt-PA,对照组)。结果 2组30、90d神经功能恢复良好及预后良好的比例差异无统计学意义(P>0.05)。脑梗死组sICH发生率低于对照组(2.2%vs 7.9%),但差异无统计学意义(P>0.05)。结论低剂量rt-PA溶栓治疗急性脑梗死的有效性不亚于高剂量rt-PA,其安全性可能更高。

引用

页码：1093 / 1095

页数：3

共 9 条

[1] 重组组织型纤溶酶原激活剂联合尿激酶治疗急性脑梗死的临床观察
张国鲁
张微微
黄勇华
范慧敏
[J]. 中华老年心脑血管病杂志, 2012, 14 (05) : 507 - 510
[2] Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies[J] . William N. Whiteley,Karsten Bruins Slot,Peter Fernandes,Peter Sandercock,Joanna Wardlaw.Stroke . 2012 (11)
[3] Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke[J] . Pornpatr A. Dharmasaroja,Sombat Muengtaweepongsa,Junya Pattaraarchachai,Permphan Dharmasaroja.Journal of Clinical Neuroscience . 2011 (6)
[4] Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)[J] . Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi.Stroke . 2010 (9)
[5] Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register[J] . Kazunori Toyoda,Masatoshi Koga,Masaki Naganuma,Yoshiaki Shiokawa,Jyoji Nakagawara,Eisuke Furui,Kazumi Kimura,Hiroshi Yamagami,Yasushi Okada,Yasuhiro Hasegawa,Kazuomi Kario,Satoshi Okuda,Kazutoshi Nishiyama,Kazuo Minematsu.Stroke . 2009 (11)
[6] Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator: A Science Advisory From the American Heart Association/American Stroke Association[J] . Gregory J. del Zoppo,Jeffrey L. Saver,Edward C. Jauch,Harold P. Adams.Stroke . 2009 (8)
[7] Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial[J] . Erich Bluhmki,ángel Chamorro,Antoni Dávalos,Thomas Machnig,Christophe Sauce,Nils Wahlgren,Joanna Wardlaw,Werner Hacke.Lancet Neurology . 2009 (12)
[8] Epidemiological transition of stroke in China?
Truelsen, Thomas
Bonita, Ruth
[J]. STROKE, 2008, 39 (06) : 1653 - 1654
[9] Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educati[J] . Harold P. Adams,Gregory del Zoppo,Mark J. Al

← 1 →